Several early clinical trials have been designed to explore the preliminary effectiveness and safety of BET inhibitors in SCLC patients.103 Inhibition of the BET family member BRD4 or the cyclin-dependent kinase 7 (CDK7) may provide potential therapeutic targets by inhibiting expression of MYC family members.28 Lysine demethylase 1A (LSD1) encodes a histone modification enzyme which is overexpressed in SCLC and many other malignant tumors.104 The LSD1 inhibition provides a promising new therapeutic target for the SCLC patients. This evidence concerns the gene MYC and small cell lung carcinoma.